Comparison
SAM-e vs L-Methylfolate
SAM-e targets broad methylation and mood; methylfolate hits homocysteine and MTHFR bottlenecks.
SAM-e
Methyl Donor / Liver Support
L-Methylfolate
Methyl Donor / Folate Cofactor
Effectiveness Profile
At a Glance
| SAM-e | L-Methylfolate | |
|---|---|---|
| Type | Supplement | Supplement |
| Legal status | OTC | OTC |
| Half-life | 1.4–1.7 hours (IV); plasma elevations resolve within ~24h after oral dosing | 3–5 hours (plasma); RBC folate plateaus over 8–12 weeks |
| Preferred route | Oral | Oral |
| Dose frequency | twice-daily | once-daily |
| Beginner dose | 200–400 mg | 0.4–1 mg |
| Intermediate dose | 400–800 mg | 1–5 mg |
| Advanced dose | 1200–1600 mg | 7.5–15 mg |
| Cycle length | 4–12 wks | 8–52 wks |
| Bioavailability | 10% | 90% |
| Time to peak | 4h | 1.5h |
| Active duration | 12h | 8h |
| Storage | Refrigerate enteric-coated tablets in sealed blister; free cation is unstable — stabilized salts (disulfate-tosylate or 1,4-butanedisulfonate) only | Room temperature, dry, away from light |
| PCT required | No | No |
| Ancillaries required | No | No |
| Safe for women | Yes | Yes |
Verdict
SAM-e wins for: Broad-spectrum methylation support (across >150 enzymatic processes), dual-action on mood and joint pain, rapid onset of effect (days to a week), and efficacy in scenarios with oxidative stress (oral AAS, cholestasis, heavy training-induced inflammation). Versatile for hepatic support and post-cycle mood management.
L-Methylfolate wins for: Cleanest homocysteine control (especially for MTHFR carriers), well-tolerated at maintenance and multi-mg doses, low risk of serotonin syndrome, can be safely stacked with SSRIs, and easier to source (OTC, pure-grade, bulk caps). Ideal for long-term cycle support or micronutrient gap-filling with minimal side effect profile.
Pick A or B?
Pick SAM-e if:
- The protocol calls for aggressive hepatic protection (oral AAS cycles, cholestasis risk).
- Joint pain, inflammatory markers, or OA symptoms are stalling progress.
- Mood support is the primary concern post-cycle or on compounds with strong dopaminergic/serotonergic hits (tren, finasteride).
- Rapid relief is needed for joint or mood-related symptoms (onset often seen in days).
- Other methyl donors (folate, B12, TMG) aren't moving biomarkers sufficiently.
Pick L-Methylfolate if:
- Controlling homocysteine is the main goal (especially with known MTHFR SNPs or heavy oral use).
- The stack includes orals but hepatic enzymes and glutathione aren't the bottleneck.
- SSRI, SNRI, or MAOI are on board and serotonin syndrome risk must be minimized.
- Bulk, retail-grade sourcing or price sensitivity is a priority.
- Filling in micronutrient B-complex gaps for hair, skin, or general physiology without stacking riskier compounds.